|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
16 December 2017 |
|
Main ID: |
NCT02462681 |
|
Date of registration:
|
30/05/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery
|
|
Scientific title:
|
Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery |
|
Date of first enrolment:
|
May 2015 |
|
Target sample size:
|
90 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02462681 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
|
Phase:
|
Phase 1/Phase 2
|
|
|
Countries of recruitment
|
|
Egypt
| | | | | | | |
|
Contacts
|
|
Name:
|
Sahar A. Mohamed, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Lecturer of anesthesia, ICU and pain management- South Egypt Cancer Institute- Assuit University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- all patients scheduled for elective modified radical mastectomy with axillary
dissection will be enrolled in the study
Exclusion Criteria:
- patients with a known allergy to the study drugs
- patients with bleeding diathesis
- patients with infection at the site of injection
- patients with central neuropathy
- patients with liver impairment
- patients with renal impairment
- drugs or alcohol abusers
- patients with psychiatric illnesses
Age minimum:
25 Years
Age maximum:
70 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Acute Pain
|
|
Chronic Pain
|
|
Intervention(s)
|
|
Drug: paravertebral block
|
|
Primary Outcome(s)
|
|
changes in pain intensity score from baseline
[Time Frame: at 2,4,6,12,24,36and 48 hour postoperatively]
|
|
Secondary Outcome(s)
|
|
chronic neuropathic pain
[Time Frame: 1st,2nd and 3rd postoperative months]
|
|
side effect
[Time Frame: 2,4,6,12,24,36and 48 hour postoperatively.]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|